Market Overview:
The global irinotecan market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cancer, rising demand for novel therapeutics, and growing focus on targeted therapies. By type, the irinotecan hydrochloride injection 40mg segment is expected to account for the majority share of the market in 2018. By application, colon cancer is expected to account for the majority share of the market in 2018. In terms of region, North America is expected to dominate the global irinotecan market in 2018.
Product Definition:
Irinotecan is a chemotherapy drug used to treat cancer. It belongs to a group of drugs called topoisomerase inhibitors.
Irinotecan Hydrochloride Injection 40mg:
Irinotecan is a member of the family of drugs called as antineoplastics. It's main function is to stop the growth of cancer cells. This drug has many side effects which can be seen in patient’s eyes, mouth, and skin. By understanding these side effects it helps to manage them so that they don’t become stronger symptoms for the patient.
Other:
Other ingredients in Irinotecan market include Dextrose, Sodium Bicarbonate, Hydrochloric Acid and Water for Injection. Other ingredients are used to adjust pH levels during the manufacturing process of irinotecan. It helps in increasing the speed of dissolution by making it more acidic or basic as per requirement which is further expected to drive its demand over the forecast period.
Application Insights:
Colon cancer application segment led the global irinotecan market in 2017. The drug is used for the treatment of colorectal cancer, which has spread to other parts of the body. As per American Cancer Society (ACS), around 60% of patients with colon or rectal cancer are diagnosed in advanced stages, which means that 40% of people with this disease are not aware that they have it until it is too late and spreads to other parts of the body. This situation demands effective drugs like irinotecan so as to cure these cancers at an early stage before they spread further and become incurable.
The drug also shows promising results against liver tumors such as hepatocellular carcinoma (HCC).
Regional Analysis:
North America dominated the global irinotecan market in 2017. This is attributed to the presence of a large number of cancer patients, high adoption of oncology drugs, and favorable reimbursement policies in this region. In addition, increasing government funding for R&D activities pertaining to colon cancer and rectal cancer is also expected to boost growth over the forecast period. Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising incidences of colorectal cancer coupled with growing healthcare spending by consumers and governments in this region. Moreover, increasing awareness about early diagnosis among people will drive regional demand further.
Irinotecan hydrochloride injection (HCl) has been approved for sale only within Japan until 2016; however it was sold internationally through parallel importation until then as Japan did not have an active pharmaceutical ingredient manufacturer at that time (late 2015).
Growth Factors:
- Increasing incidence of colorectal cancer: The incidence of colorectal cancer is increasing globally due to the changing lifestyle and dietary habits. This will drive the demand for Irinotecan and other related drugs in the coming years.
- Growing awareness about early diagnosis and treatment: There is a growing awareness among people about the importance of early diagnosis and treatment for various diseases, including colorectal cancer. This is likely to boost the demand for Irinotecan in the near future.
- Rising number of clinical trials: A large number of clinical trials are being conducted on Irinotecan across the world, which is indicative of its potential as a therapeutic agent against colorectal cancer. This will create new opportunities for players operating in this market over the next few years.
- Technological advancements: The development of novel technologies such as targeted therapy has revolutionized how cancers are treated nowadays, resulting in better patient outcomes with fewer side effects than traditional chemotherapy regimens like those containing Irinotecan drug molecule .This trend is likely to benefit players operating in this market over medium to long term future period . 5) Availability Of Alternate Drugs With Similar Mechanism Of Action : There are few alternate drugs available with similar mechanism or action as irinotecan , which might hamper growth prospects if these drugs are launched at lower prices
Scope Of The Report
Report Attributes
Report Details
Report Title
Irinotecan Market Research Report
By Type
Irinotecan Hydrochloride Injection 40mg, Other
By Application
Colon Cancer, Rectal Cancer
By Companies
West-Ward Pharmaceuticals, Pfizer, Teva, Actiza Pharmaceutical, Getwell, Taj Pharma, Cipla, Salius, West-Ward Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
148
Number of Tables & Figures
104
Customization Available
Yes, the report can be customized as per your need.
Global Irinotecan Market Report Segments:
The global Irinotecan market is segmented on the basis of:
Types
Irinotecan Hydrochloride Injection 40mg, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Colon Cancer, Rectal Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- West-Ward Pharmaceuticals
- Pfizer
- Teva
- Actiza Pharmaceutical
- Getwell
- Taj Pharma
- Cipla
- Salius
- West-Ward Pharmaceuticals
Highlights of The Irinotecan Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Irinotecan Hydrochloride Injection 40mg
- Other
- By Application:
- Colon Cancer
- Rectal Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Irinotecan Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Irinotecan is a chemotherapy drug used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major players in the irinotecan market are West-Ward Pharmaceuticals, Pfizer, Teva, Actiza Pharmaceutical, Getwell, Taj Pharma, Cipla, Salius, West-Ward Pharmaceuticals.
The irinotecan market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Irinotecan Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Irinotecan Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Irinotecan Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Irinotecan Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Irinotecan Market Size & Forecast, 2020-2028
4.5.1 Irinotecan Market Size and Y-o-Y Growth
4.5.2 Irinotecan Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Irinotecan Hydrochloride Injection 40mg
5.2.2 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Colon Cancer
6.2.2 Rectal Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Irinotecan Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Irinotecan Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Irinotecan Hydrochloride Injection 40mg
9.6.2 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Colon Cancer
9.10.2 Rectal Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Irinotecan Hydrochloride Injection 40mg
10.6.2 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Colon Cancer
10.10.2 Rectal Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Irinotecan Hydrochloride Injection 40mg
11.6.2 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Colon Cancer
11.10.2 Rectal Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Irinotecan Hydrochloride Injection 40mg
12.6.2 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Colon Cancer
12.10.2 Rectal Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Irinotecan Hydrochloride Injection 40mg
13.6.2 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Colon Cancer
13.10.2 Rectal Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Irinotecan Market: Competitive Dashboard
14.2 Global Irinotecan Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 West-Ward Pharmaceuticals
14.3.2 Pfizer
14.3.3 Teva
14.3.4 Actiza Pharmaceutical
14.3.5 Getwell
14.3.6 Taj Pharma
14.3.7 Cipla
14.3.8 Salius
14.3.9 West-Ward Pharmaceuticals
